Completed PHASE3 INTERVENTIONAL NCT00002377

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Sponsor: Hoffmann-La Roche

Conditions Cytomegalovirus Retinitis HIV Infections

Interventions Ganciclovir Valganciclovir

Updated 7 times since 2017 Last updated: May 15, 2017 Started: Jan 31, 1997 Primary completion: Dec 31, 2002 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cytomegalovirus Retinitis and HIV Infections, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 7 data snapshots since 1997. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2017 [monthly]

Completed PHASE3

First recorded

Jan 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Austin, United States , Boston, United States , Durham, United States , Irvine, United States , La Jolla, United States , Miami, United States , Montreal, Canada , New York, United States , San Diego, United States and 4 more locations